Comparative effectiveness of medical treatments / Meter [i.e. Peter] Villa and Sophia Brun, editors.

Format:

Book

Contributor:

Villa, Peter.

Brun, Sophia.

Series:

Health care issues, costs, and access.

Novinka (Series)

Health care issues, costs and access series

Novinka

Language:

English

Subjects (All):

Drugs--Effectiveness.

Drugs.

Therapeutics.

Therapeutics--Costs.

Physical Description:

1 online resource (106 p.)

Edition:

1st ed.

Place of Publication:

New York : Nova Science Publishers, Inc., c2009.

Language Note:

English

Summary:

This book explores the comparative effectiveness of medical treatments as applied in the health care sector. An analysis of comparative effectiveness is simply a comparison of the impact of different options that are available for treating a given medical condition for a particular set of patients. These studies may compare both similar treatments, such as competing drugs, or they may analyze very different approaches, such as surgery and drug therapy. The analysis may focus only on the relative medical benefits and risks of each option, or it may go on to weigh both the costs and the benefits of those options. In some cases, a given treatment may be found more effective for all types of patients, but more commonly a key issue is determining which specific types would benefit most from it. Although some information about the effectiveness of new drugs, medical devices, or procedures is often available, rigorous comparisons of different treatment options are less common. Thus, this book compares and discusses which treatments work best for which patients and whether the added benefits of more-effective but more-expensive services are sufficient to warrant their added costs.

Contents:

Intro

COMPARATIVE EFFECTIVENESS OF MEDICAL TREATMENTS

LIBRARY OF CONGRESS CATALOGING-IN-PUBLICATION DATA

CONTENTS

PREFACE

Chapter 1: RESEARCH ON THE COMPARATIVE EFFECTIVENESS OF MEDICAL TREATMENTS: OPTIONS FOR AN EXPANDED FEDERAL ROLE BEFORE THE SUBCOMMITTEE ON HEALTH COMMITTEE ON WAYS AND MEANSU.S. HOUSE OF REPRESENTATIVES∗JUNE 12, 2007

BACKGROUND ON PAST AND CURRENT EFFORTS

What Is Comparative Effectiveness?

Research in the Private Sector

Past and Current Federal Efforts to Assess Medical Treatments

Comparative Effectiveness in Other Countries

OPTIONS FOR ORGANIZING AND FUNDING FEDERAL RESEARCH EFFORTS

ISSUES AND CHALLENGES IN COMPARING THE EFFECTIVENESS OF TREATMENTS

Methods of Research

Scope of Analysis and Dissemination of Results

POTENTIAL IMPLICATIONS FOR HEALTH CARE SPENDING

Potential for Savings on Health Care

Possible Responses Under Private and Public Insurance Plans

CONCLUSION

REFERENCES

Chapter 2: PRODUCING COMPARATIVE-EFFECTIVENESS INFORMATION

CONTEXT FOR MEDICARE PAYMENT POLICY

DEFINING COMPARATIVE EFFECTIVENESS

The Private Sector Does Not Systematically Produce andDisseminate Objective Comparative-Effectiveness Information

Conducting Comparative-Effectiveness Studies Is Not the PrimaryFocus of Any Federal Agency

The United States Needs to Produce More Credible Comparative-Effectiveness Information

Comparative Information Could Help Payers Make Better Policies

More Comparative Information Could Help Support BetterDecision Making by Patients and Providers

Functions and Activities of a Comparative-Effectiveness Entity

Structuring an Entity to Examine and Report on ComparativeEffectiveness

CONCLUSION.

Chapter 3: TESTIMONY OF STEVEN M. TEUTSCH, M.D., M.P.H. EXECUTIVE DIRECTOR, OUTCOMES RESEARCH, EXTERNAL MEDICAL AND SCIENTIFIC AFFAIRS,MERCK &amp

CO., INC. BEFORE THE HOUSE WAYS AND MEANS, HEALTH SUBCOMMITTEE CONCERNING COMPARATIVE EFFECTIVENESS JUNE 12, 2007

MERCK AND COMPARATIVE EFFECTIVENESS

NECESSARY CHARACTERISTICS OF THE NATIONAL COMPARATIVE EFFECTIVENESS EFFORT

STAKEHOLDER CONCERNS

SELECTED PUBLICATIONS RELEVANT TO COMPARATIVE EFFECTIVENESS

Chapter 4: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF CAROLYN M. CLANCY, M.D., DIRECTOR,AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, ROCKVILLE, MARYLAND TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007

EFFECTIVE HEALTH CARE PROGRAM

COMPARATIVE EFFECTIVENESS REVIEWS

Gastroesophageal Reflux Disease (GERD)

Breast Cancer Diagnosis

Managing Anemia in Cancer Patients

Osteoarthritis Drugs

Renal Artery Stenosis

Off-Label Use of Atypical Antipsychotics

Second-Generation Antidepressants

Health Information Technology

Chapter 5: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF DAVID DALE, M.D.,PRESIDENT, AMERICAN COLLEGE OF PHYSICIANS TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007

THE PUBLIC NEED FOR COMPARATIVE CLINICAL EFFECTIVENESS RESEARCH

USE OF COMPARATIVE EFFECTIVENESS IN BENEFIT DESIGN DECISIONS

COMPARATIVE CLINICAL EFFECTIVENESS RESEARCH AND SHARED DECISION-MAKING

SUMMARY AND CONCLUSION

Chapter 6: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF GAIL SHEARER, DIRECTOR, HEALTH POLICY ANALYSIS, CONSUMERS UNION TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007

REFERENCES.

Chapter 7: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF SUSAN HEARN, PH.D., SENIOR PROJECT MANAGER IN ENVIRONMENT HEALTH AND SAFETY, DOW CHEMICAL COMPANY, MIDLAND, MICHIGAN TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007

Chapter 8: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF THE HONORABLE THOMAS ALLEN, A REPRESENTATIVE IN CONGRESS FROM THE STATE OF MAINE TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007

Chapter 9: BACKGROUND TO HEARING ON STRATEGIES TO INCREASE INFORMATION ON COMPARATIVE CLINICAL EFFECTIVENESS FROM HOUSE WAYS AND MEANS HEALTH SUBCOMMITTEE CHAIRMAN PETE STARK

FOCUS OF THE HEARING

INDEX.

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

Description based on print version record.

ISBN:

1-61728-193-X

OCLC:

923662221